Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through a biotech filing that runs 300 pages of clinical data is hard enough; add rare-disease terminology and Rhythm Pharmaceuticals鈥� disclosures become downright daunting. Whether you need the latest Rhythm Pharmaceuticals quarterly earnings report 10-Q filing or want to track Rhythm Pharmaceuticals insider trading Form 4 transactions before the next data read-out, the challenge is finding what matters fast.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q, 8-K and proxy statement the moment it posts to EDGAR and delivers plain-language highlights鈥攖hink cash runway trends, pivotal-trial costs, and patent-expiry clocks鈥攕o you can focus on decisions, not deciphering jargon. Looking for Rhythm Pharmaceuticals annual report 10-K simplified? It鈥檚 already condensed. Need Rhythm Pharmaceuticals Form 4 insider transactions real-time? Alerts arrive in seconds.
- AI-powered summaries that answer 鈥渦nderstanding Rhythm Pharmaceuticals SEC documents with AI鈥� in minutes
- AG真人官方-time feeds for Rhythm Pharmaceuticals executive stock transactions Form 4
- Side-by-side comparison of sequential trials inside every 10-Q earnings report filing analysis
- Key excerpts from Rhythm Pharmaceuticals proxy statement executive compensation鈥擱SUs, milestone bonuses and all
- Rhythm Pharmaceuticals 8-K material events explained in plain English, from FDA label updates to financing rounds
Investors use these insights to monitor insider sentiment ahead of top-line data, gauge cash burn vs. runway, and benchmark executive incentives against regulatory goals. No more scrolling line-by-line; our platform surfaces what biopharma specialists actually need鈥攆rom patient enrollment numbers to royalty obligations鈥攕o your biotech diligence stays sharp and timely.
ServiceTitan, Inc. (TTAN) has filed a Form 144 indicating intent to sell 6,047 Class A common shares through Merrill Lynch on or about 9 July 2025. At the most recent market price used in the filing, the transaction is valued at $663,900. The company has 77.27 million shares outstanding, so the proposed sale represents roughly 0.008 % of the float and is therefore immaterial from a dilution standpoint.
The filing also discloses extensive prior sales by funds affiliated with Bessemer Venture Partners and 15 Angels II LLC over the last three months. In aggregate, about 932,243 shares were sold between 10 June 2025 and 8 July 2025, generating approximately $97.5 million in gross proceeds. Taken together, these past divestitures equal roughly 1.2 % of outstanding stock, suggesting a continued exit strategy by early investors.
No new operational or financial performance data are included in this Form 144. The sole purpose is to give notice of the contemplated share sale and to provide transparency on recent secondary-market activity by significant shareholders. While the single upcoming sale is minor, sustained distribution by venture funds can put technical pressure on the share price and may be interpreted by some investors as a lack of long-term commitment from early backers.
Biotechnology Value Fund and affiliated entities have filed a Schedule 13G disclosing a collective 7.4% passive stake in Nektar Therapeutics (NASDAQ: NKTR). The filing, dated 9 July 2025 with an event date of 1 July 2025, reports aggregate beneficial ownership of 1,276,595 common shares out of 17,301,061 shares outstanding following the company鈥檚 recent public offering.
The ownership is spread across multiple Delaware and Cayman-based vehicles: Biotechnology Value Fund (LP) holds 661,758 shares (3.8%), Biotechnology Value Fund II (LP) holds 517,813 shares (3.0%), and Biotechnology Value Trading Fund OS (LP) holds 71,367 shares (<1%). Control is exercised jointly through the general partners BVF GP Holdings LLC and BVF Partners L.P., with Mark N. Lampert signing on behalf of each entity. All shares are held with shared voting and dispositive power; none of the reporting persons claims sole authority.
The filing is made on Form 13G鈥攊ndicating a passive investment intent rather than an activist position鈥� and includes the customary certification that the securities were not acquired to influence control of the issuer. No other material transactions, derivatives, or lock-up arrangements are disclosed.
Key take-aways for investors: BVF鈥檚 aggregated 7.4% stake makes it one of the largest outside shareholders of Nektar, signalling confidence from a specialist biotech investor group. However, because the filing is passive, immediate governance or strategic changes should not be expected.
OneStream, Inc. (OS) Form 4 filing: Director Jonathan D. Mariner sold 6,630 Class A common shares on 07/07/2025 at a weighted-average price of $26.59 under a Rule 10b5-1 trading plan adopted on 02/28/2025. After the sale, Mariner still beneficially owns 40,280 shares, which include unvested restricted stock units. No derivative transactions were reported.
The transaction reduces Mariner鈥檚 direct holdings by roughly 14% but maintains a sizable position, suggesting portfolio rebalancing rather than a full exit. The use of a pre-arranged plan limits the signaling effect because it indicates the sale was scheduled in advance and not driven by new, undisclosed information.
OneStream, Inc. (OS) Form 4 filing: Director Jonathan D. Mariner sold 6,630 Class A common shares on 07/07/2025 at a weighted-average price of $26.59 under a Rule 10b5-1 trading plan adopted on 02/28/2025. After the sale, Mariner still beneficially owns 40,280 shares, which include unvested restricted stock units. No derivative transactions were reported.
The transaction reduces Mariner鈥檚 direct holdings by roughly 14% but maintains a sizable position, suggesting portfolio rebalancing rather than a full exit. The use of a pre-arranged plan limits the signaling effect because it indicates the sale was scheduled in advance and not driven by new, undisclosed information.
ChargePoint Holdings, Inc. (NYSE: CHPT) filed an 8-K covering board and corporate actions taken between 7-7-2025 and 7-9-2025.
Key personnel change: Chief Legal Officer & Corporate Secretary Rebecca Chavez will resign effective July 25, 2025 to pursue another opportunity.
2025 Annual Meeting results (58.6 % quorum):
- Four Class II directors were re-elected to serve until 2028.
- PWC ratified as independent auditor for FY 2026.
- Advisory 鈥渟ay-on-pay鈥� passed (80.3 m for vs. 15.2 m against).
- Reverse Stock Split amendment approved (232.9 m for, 34.1 m against) allowing a split ratio between 1-for-2 and 1-for-30.
- Corporate Opportunity Waiver amendment failed.
- Adjournment authority approved.
Reverse stock split executed: On July 9, 2025 the Nominating & Governance Committee set the ratio at 1-for-20, effective 12:01 a.m. ET on July 28 2025. Outstanding shares will drop from ~467.1 million to ~23.4 million; equity awards, warrants and convertible notes will be proportionally adjusted. No fractional shares will be issued; cash will be paid in lieu. The action targets regaining NYSE compliance after falling below the US$1.00 minimum price in February 2025. Trading symbol remains CHPT; new CUSIP 15961R 303.
Material implications for investors:
- The split should immediately lift the per-share price and preserve the NYSE listing, but it does not improve underlying fundamentals.
- Share count reduction may increase per-share metrics (EPS, book value) mechanically, with no change in proportional ownership.
- Departure of the CLO introduces near-term succession and governance risk.
- Failure of the corporate opportunity waiver suggests some shareholder concern over governance amendments.
ChargePoint Holdings, Inc. (NYSE: CHPT) filed an 8-K covering board and corporate actions taken between 7-7-2025 and 7-9-2025.
Key personnel change: Chief Legal Officer & Corporate Secretary Rebecca Chavez will resign effective July 25, 2025 to pursue another opportunity.
2025 Annual Meeting results (58.6 % quorum):
- Four Class II directors were re-elected to serve until 2028.
- PWC ratified as independent auditor for FY 2026.
- Advisory 鈥渟ay-on-pay鈥� passed (80.3 m for vs. 15.2 m against).
- Reverse Stock Split amendment approved (232.9 m for, 34.1 m against) allowing a split ratio between 1-for-2 and 1-for-30.
- Corporate Opportunity Waiver amendment failed.
- Adjournment authority approved.
Reverse stock split executed: On July 9, 2025 the Nominating & Governance Committee set the ratio at 1-for-20, effective 12:01 a.m. ET on July 28 2025. Outstanding shares will drop from ~467.1 million to ~23.4 million; equity awards, warrants and convertible notes will be proportionally adjusted. No fractional shares will be issued; cash will be paid in lieu. The action targets regaining NYSE compliance after falling below the US$1.00 minimum price in February 2025. Trading symbol remains CHPT; new CUSIP 15961R 303.
Material implications for investors:
- The split should immediately lift the per-share price and preserve the NYSE listing, but it does not improve underlying fundamentals.
- Share count reduction may increase per-share metrics (EPS, book value) mechanically, with no change in proportional ownership.
- Departure of the CLO introduces near-term succession and governance risk.
- Failure of the corporate opportunity waiver suggests some shareholder concern over governance amendments.
Splash Beverage Group, Inc. (SBEV) filed a new Form D notice indicating completion of most of a private financing conducted under Reg D Rule 506(b). The company has offered up to $36.25 million in a mix of equity, preferred shares, and warrants associated with a business-combination transaction.
- Capital raised: $33.321 million (92% of the stated maximum) has already been sold to 30 investors; $2.929 million remains available.
- Securities structure: 鈥� up to 1,250 Series A-1 preferred shares and related warrants (鈮� $1.25 M) 鈥� up to 150,000 Series B preferred shares in exchange for 鈮� $15 M of debt 鈥� 20,000 Series C convertible preferred shares issued for assets acquired in a business-combination transaction.
All securities include options, warrants, or conversion rights that could create additional equity. - Business purpose: The filing confirms the Series C issuance was payment for 鈥渃ertain assets鈥� of a third-party seller, signalling an acquisition-related expansion tactic.
- Cost efficiency: No sales commissions or finder鈥檚 fees were paid; only $73k (estimated) of proceeds are earmarked for payments to executives/directors.
- Offering profile: New notice, first sale on 25 Jun 2025; expected to close within one year. The issuer declined to disclose revenue range and used Rule 506(b), limiting solicitation to accredited investors and permitting resale restrictions.
Investor takeaway: The raise materially boosts SBEV鈥檚 liquidity for debt reduction and asset acquisition with minimal transaction costs. However, the heavy reliance on preferred shares, warrants, and convertible securities may lead to future dilution and signals ongoing capital-intensive growth needs.
Rhythm Pharmaceuticals (RYTM) 鈥� insider Form 4 filing
Chief Scientific Officer Alastair Garfield settled 4,445 restricted stock units on 1-Jul-2025, receiving an equal number of common shares. On 2-Jul-2025 he sold 1,319 of those shares in two trades at prices of $64.81 and $64.60 under a pre-arranged Rule 10b5-1 plan adopted 25-Jun-2024, with the stated purpose of covering withholding taxes. After the transactions he retains 3,126 directly held shares and 13,333 unvested RSUs that vest 25 % annually through 1-Jul-2028, subject to continued employment. No other equity instruments were created or disposed of. Given the modest size of the sale relative to Rhythm鈥檚 share count and its tax-related rationale, the event is viewed as routine compensation management with limited signaling value for investors.
Rhythm Pharmaceuticals director Camille L. Bedrosian received new equity compensation grants on June 24, 2025, consisting of:
- Stock Options: 7,037 options to purchase common stock at an exercise price of $63.66 per share, expiring June 23, 2035
- Restricted Stock Units (RSUs): 4,712 RSUs, each convertible into one share of common stock
Both grants will fully vest on the earlier of June 24, 2026 or the day before the 2026 annual stockholder meeting, subject to continued service. The options provide the right to purchase shares at the fixed exercise price, while the RSUs represent a contingent right to receive shares with no purchase requirement. This appears to be part of the company's regular director compensation program.
Rhythm Pharmaceuticals (Nasdaq: RYTM) filed an 8-K disclosing the June 24 2025 Annual Meeting results and a governance change.
- Officer exculpation amendment: Stockholders approved a charter change (55.5 M FOR / 3.5 M AGAINST) extending Delaware-permitted liability protection to certain officers; became effective upon June 25 2025 filing.
- Director elections: Jennifer Good re-elected with 55.6 M votes; Edward T. Mathers retained his seat with 35.2 M votes.
- Auditor confirmation: Ernst & Young LLP ratified for FY-2025 with 60.6 M (99.7 %) FOR.
- Say-on-pay: Executive compensation passed (40.9 M FOR, 18.1 M AGAINST).
- Quorum: 60.7 M votes present, representing 92.7 % of eligible votes.
No operational or financial metrics were updated; the lone material item is the officer liability shield, which may dilute shareholder recourse.
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
What does Rhythm Pharmaceuticals specialize in?
What is the company鈥檚 lead product?
How does IMCIVREE work?
What kind of diseases does Rhythm Pharmaceuticals target?
What is the global regulatory status of Rhythm鈥檚 therapies?
Does the company have a diversified product pipeline?
How does Rhythm Pharmaceuticals maintain its expertise?
What differentiates Rhythm in the competitive biopharmaceutical landscape?
